Ontario expanding publicly funded private surgical and diagnostic centres
Ontario is expanding its suite of publicly funded private community surgical and diagnostic centres.
Premier Doug Ford says the province is investing $155 million over the next two years to create 57 new centres for MRI and CT scans and gastrointestinal endoscopy services.
Ford says the new clinics will help ease the burden on hospitals and reduce wait times.
The province says it will add 35 new centres for MRI and CT scans that it says will serve more than 800,000 patients.
And it will add 22 centres to deliver endoscopy services.
Ford's Progressive Conservative government first introduced sweeping changes to the delivery of health care in 2023 in response to a massive surgical and diagnostic test backlog.
This report by The Canadian Press was first published June 27, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
a day ago
- Newsweek
Parents Welcome Baby Boy, 3 Months Later Realize Something Is Wrong
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A woman has revisited the moment she began to suspect something wasn't right with her newborn son and the emotional journey that followed as she sought to find answers. Carli Cowie from Moray in Scotland, took to her TikTok account, Carlirose33, to share pictures of Noah from when he was born on November 3, 2018 and in the blissful days that followed. "The best day of my life," Cowie wrote alongside the images. "I couldn't stop staring at him. I couldn't believe this beautiful baby was ours. Our hearts were so full of love." By the time Noah's six-week check-up rolled around, everything seemed to be on track. "He was hitting milestones," Cowie said. But by 12 weeks, Cowie and her husband had started to notice "something wasn't right." Cowie told Newsweek: "He wasn't making eye contact with us, wasn't following toys and his eyes were wobbling." Carli first noticed an issue with Noah's eyes when he was just 12 weeks old. Carli first noticed an issue with Noah's eyes when he was just 12 weeks old. TikTok/carlirose33 They made an appointment for Noah to see their doctor, who then referred them on to an ophthalmologist. At this point, there were concerns Noah could have retinoblastoma, a rare type of cancer affecting the retina. Read more Woman remembers one thing dad "regretted"—30 years later she makes it right Woman remembers one thing dad "regretted"—30 years later she makes it right In order to find out if this was the case, doctors needed to dilate his pupils to check. All this time, Cowie and her husband were left facing an anxious wait for answers. "We were so worried and didn't know what the outcome was going to be," she said. She estimates it took three months from that initial doctor's appointment, for them to get an understanding of Noah's condition. Doctors suspected Noah had been born with optic nerve hypoplasia, meaning his optic nerves were under-developed. The "wobbling" movement his eyes made was also thought to be a result of nystagmus, an involuntary eye movement condition that further reduces or limits vision. A delayed MRI scan eventually confirmed the heartbreaking diagnosis: Noah was blind. His parents were left in shock at the news. "We were devastated and in disbelief that this was happening to our baby," Cowie said. "We initially thought it wouldn't be something as serious as what it was, we thought he'd maybe need glasses or something along those lines." Though Cowie was rocked by the news, she managed to stay strong, with the support of her husband and family, knowing it was important to maintain a happy household for Noah's sake. "I didn't want Noah to pick up if we were upset so I always tried to be in high spirits for him," she said. "Although he was blind I kept reminding myself that he was healthy and we were grateful for that." Noah underwent regular check-ups in the years that followed with doctors careful to monitor that his weight and height was within the normal range. "If the tests weren't in normal range he would have been put on growth hormone injections until he was 18," Cowie said. Thankfully, for Noah, that wasn't needed and by the time he turned 4, he was fully discharged and ready to his way as a blind child out in the world. He's not alone in that respect. In the U.S., the CDC estimates nearly 3 percent of children under the age of 18 have blindness or vision impairment. Noah Cowie is 6 and thriving now. Noah Cowie is 6 and thriving now. TikTok/carlirose33 It's a life that comes with its own unique challenges for his mom and dad. "One of the biggest I would say is his safety and making sure there is nothing in his way or lying out for him to trip over or bump into," Cowie said. But it is one that Noah, now 6, is thriving in, with a little help from mom, dad and his two-year-old sister Ocean. "He's doing really well. Noah is always keen to try new things and we are amazed with how well he gets on," Callie said. "He's a clever boy and enjoys learning. He's at the early stages of learning braille and learning to use his cane with support." Callie's TikTok video, chronicling their journey with Noah went viral, amassing over 640,000 views since being posted earlier this month. She's incredibly proud of her son and hopes this video and others like it help any families who may be going through similar situations with a young child. Noah's story isn't one of heartbreak, it's one of hope. "I wanted to show everyone how amazing he is," Callie said. "Being blind hasn't stopped him from doing anything."
Hamilton Spectator
2 days ago
- Hamilton Spectator
Quebec air ambulance company pays homage to four victims of helicopter crash
MONTREAL - The company that operated an air ambulance that crashed on Quebec's North Shore on June 20 is honouring the four victims who perished. Airmedic says three of its crew members died as heroes, along with an American patient. Four crew members and the patient were aboard the Airmedic helicopter when it went down in a remote area north of Natashquan, about 1,000 kilometres northeast of Montreal. The company described the patient as a quiet woman, entirely devoted to her family. One crew member survived, the body of another person was found on Monday, and the other three victims' bodies were recovered by provincial police on Wednesday. The Quebec coroner's office says the victims are Sébastien De Lutio, 50, from Lac-Beauport; Olivier Blouin, 25, from Pont-Rouge; Sébastien Groulx, 50, from Longueuil; and patient Claire Tripp, 78, from the U.S. state of Maine. On its website, Airmedic says its employees were faithful to their mission until the very last moment, and saluted their dedication, courage, and humanity. This report by The Canadian Press was first published June 27, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Business Wire
2 days ago
- Business Wire
PRD Therapeutics宣布啟動PRD001的首例人體研究
東京--(BUSINESS WIRE)--(美國商業資訊)-- PRD Therapeutics, Inc.是一家臨床階段公司，專注于開發靶向純合子家族性高膽固醇血症(HoFH)和代謝功能障礙相關脂肪性肝病(MASH/MASLD)的新型脂質代謝調節劑。該公司今日宣布，近期已啟動PRD001的首例人體(FIH)臨床試驗給藥。PRD001是一款同類首創的SOAT2（原稱ACAT2）選擇性抑制劑。 PRD Therapeutics執行長兼共同創辦人Kanji Hosoda博士表示：「我們很高興啟動PRD001臨床試驗的給藥。此前已展開過多項針對SOAT1/2雙重抑制劑或SOAT1選擇性抑制劑的臨床試驗，但這是第一個針對SOAT2選擇性抑制劑的臨床試驗。多項關於SOAT1或2基因敲除小鼠的研究結果已發表，顯示僅敲除或抑制SOAT2對證明安全性和有效性至關重要。PRD001是全球第一個且唯一的SOAT2選擇性抑制劑，可望也在人體中展現安全性和有效性。我們的臨床前動物模型（LDL-R KO小鼠；HoFH模型，以及高脂飲食誘導的MASH模型小鼠）顯示，PRD001可降低血液和肝臟脂質水準，抑制脂肪肝和動脈粥樣硬化的進展，且無不良事件。對於LDL受體活性缺失或極低的HoFH病患，PRD001可望成為同類第一個有效且安全的口服療法。」 該FIH 1期研究旨在評估PRD001在成年健康志願者中的安全性、耐受性、藥物動力學及早期療效跡象（LDL-C降低效應，以及使用MRI-PDFF檢測的肝臟脂肪量化值）。更多資訊可在 NCT07034183 查詢。 關於PRD001 PRD001是同類首創的口服小分子SOAT2選擇性抑制劑。它透過單一藥物獨特控制脂質代謝的三大關鍵途徑：肝臟膽固醇合成、小腸膽固醇吸收以及血液LDL-C攝取，從而強效降低血液LDL-C水準，且不依賴LDL受體。 本研發專案由日本醫療研究開發機構(AMED)透過 製藥初創企業生態系統強化計畫 提供支援（專案名稱：「同類首創口服脂質代謝調節劑PRD001的開發及脂質代謝紊亂的POC驗證」）。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
